

In the Specification:

Page 1, between line 3 (beginning "Dye" in the title) and line 4 (beginning "The present.."), please insert the heading: **BACKGROUND OF THE INVENTION**

G 1

Page 1, between line 20 and 21 (between the third and fourth full paragraph of text), please insert the heading: **SUMMARY OF THE INVENTION**

G 2

Page 2, between lines 14 and 15, please insert the heading:

G 3

DESCRIPTION OF THE PREFERRED EMBODIMENTS

In the Claims:

Please cancel original claims 1 and 7 without prejudice and replace the original claims 2 to 6 and 9 to 13 with the following amended claims:

SEARCHED
SERIALIZED
INDEXED
FILED

G 4

2(amended). Cosmetic preparation according to claim 8, wherein Q denotes methyl, ethyl, phenyl, biphenyl, C₆H₄R₃, C₆H₃R₃R₄ or C₆H₂R₃R₄R₅, wherein R₃, R₄ and R₅ are equal or different and, independently of each other, stand for F, Cl, Br, I, CN, NO₂, CF₃, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, monohydroxy-(C₁-C₄)-alkyl, polyhydroxy-(C₂-C₄)-alkyl, mono-(C₁-C₄)-alkoxy-(C₁-C₄)-alkyl, (C₁-C₄)-alkylthio, hydroxy, NR^dR^e, CHO, COR^f, COOH, COOR^g, CONHR^h or NHCORⁱ, wherein R^d and R^e, independently of each other, denote hydrogen, a (C₁-C₄)-alkyl group, a monohydroxy(C₁-C₄)-alkyl group, a polyhydroxy-(C₂-C₄)-alkyl group or an optionally substituted aromatic carbon ring, and R^f, R^g, R^h and Rⁱ, independently of each other, denote a (C₁-C₄)-alkyl group or an optionally substituted aromatic carbon ring.

3(amended). Cosmetic preparation according to claim 8, wherein X denotes oxygen or NR^a, with R^a denoting hydrogen, a (C₁-C₄)-alkyl group, a mono-hydroxy-(C₁-C₄)-alkyl group, a polyhydroxy-(C₂-C₄)-alkyl group or a mono-(C₁-C₄)-alkoxy-(C₁-C₄)-alkyl group;

R1 = R2 = hydrogen; **Q** stands for methyl, ethyl, phenyl, biphenyl, C₆H₄R₃, C₆H₃R₃R₄ or C₆H₂R₃R₄R₅, wherein R₃, R₄ and R₅ are equal or different and, independently of each other, stand for F, Cl, Br, I, CN, NO₂, CF₃, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, monohydroxy-(C₁-C₄)-alkyl, polyhydroxy-(C₂-C₄)-alkyl, mono-(C₁-C₄)-alkoxy-(C₁-C₄)-alkyl, (C₁-C₄)-alkylthio, hydroxy, NR^dR^e, CHO, COR^f, COOH, COOR^g, CONHR^h or NHCORⁱ, wherein R^d and R^e, independently of each other, denote hydrogen, a (C₁-C₄)-alkyl group, a monohydroxy(C₁-C₄)-alkyl group, a polyhydroxy-(C₂-C₄)-alkyl group or an optionally substituted aromatic carbon ring, and R^f, R^g, R^h and Rⁱ, independently of each other, denote a (C₁-C₄)-alkyl group or an optionally substituted aromatic carbon ring.

4(amended). Cosmetic preparation according to claim 8, wherein said at least one derivative of general formula (I) is selected from the group consisting of 4-amino-7-nitro-2,1,3-benzoxadiazole; 4-N,N-dimethylamino-7-nitro-2,1,3-benzoxadiazole; 4-nitro-7-methoxy-2,1,3-benzoxadiazole; 4-nitro-7-ethoxy-2,1,3-benzoxadiazole; 4-nitro-7-phenoxy-2,1,3-benzoxadiazole; 4-nitro-7-(4'-nitrophenoxy)-2,1,3-benzoxadiazole; 4-nitro-7-(2',4',6'-trimethylphenoxy)-2,1,3-benzoxadiazole; 7-nitro-4-(N-phenylamino)-2,1,3-benzoxadiazole;

4-[N-(1-naphthalenyl)amino]-7-nitro-2,1 ,3-benzoxadiazole; 4-[N-(4'-chlorophenyl)amino]-7-nitro-2,1,3-benzoxadiazole; 4-[N-(4'-fluorophenyl)-amino]-7-nitro-2,1,3-benzoxadiazole; 7-nitro-4-[N-(4'-nitrophenyl)amino]-2,1,3-benzoxadiazole; 7-nitro-4-[N-(3'-nitro-phenyl)-amino]-2,1,3-benzoxadiazole; 4-[N-(2',4'-dinitrophenyl)amino]-7-nitro-2,1,3-benzoxadiazole; 4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]benzonitrile; 4-[N-(4'-methylphenyl)amino]-7-nitro-2,1,3-benzoxadiazole; 4-[N-(2'-methyl-phenyl)amino]-7-nitro-2,1,3-benzoxadiazole; 4-[N-(4'-methoxyphenyl)amino]-7-nitro-2,1,3-benzoxadiazole; 4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]phenol; 4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-3-chloro-5-nitrophenol; 3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]phenol; 2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)-amino]phenol; N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-1,4-diaminobenzene; N,N-dimethyl-N'-(7-nitro-2,1,3-benzoxadiazol-4-yl)-1,4-diaminobenzene; N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-2-(2'-hydroxyethyl)-1,4-diaminobenzene; N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-2-(1'-hydroxyethyl)-1,4-diaminobenzene; N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-2-methoxymethyl-1,4-diaminobenzene; N,N-di-(2'-hydroxyethyl)-N'-(7-nitro-2,1,3-benzoxadiazol-4-yl)-2-nitro-1,4-diaminobenzene; methyl 4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-benzoate; 4-nitro-7-(phenylthio)-2,1,3-benzoxadiazole; 4-[(4'-chlorophenyl)thio]-7-nitro-2,1,3-benzoxadiazole; 4-[(3'-chlorophenyl)thiol-7-nitro-2,1,3-benzoxadiazole; 4-[(4'-bromo-phenyl)thiol-7-nitro-2,1,3-benzoxadiazole;

A 4
D 0 0 0 0 0 0

A 4

4-[(4'-methylphenyl)thio]-7-nitro-2,1,3-benzoxadiazole; 4-[(3'-methoxyphenyl)-thio]-7-nitro-2,1,3-benzoxadiazole; 4-nitro-7-[(4'-nitrophenyl)thiol]-2,1,3-benzoxadiazole; 2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)thio]benzoic acid; 5,7-dinitro-N-phenyl-4-amino-2,1,3-benzoxadiazole; 4-{N-[1,1'-biphenyl]-4-yl}amino}- 5,7-dinitro-2,1,3-benzoxadiazole; 4-[N-(4'-chloro-phenyl)amino]-5,7-dinitro-2,1,3-benzoxadiazole; 4-[N-(4'-bromophenyl)-amino]-5,7-dinitro-2,1,3-benzoxadiazole; 4-[N-(3'-bromophenyl)amino]-5,7-dinitro-2,1,3-benzoxadiazole; 5,7-dinitro-4-[N-(4'-nitrophenyl)amino]-2,1,3-benzoxadiazole; 5,7-dinitro-4-[N-(3'-nitro-phenyl)amino]-2,1,3-benzoxadiazole; 4-[N-(4'-methoxyphenyl)-amino]-5,7-dinitro-2,1,3-benzoxadiazole; 4-[N-(4'-methylphenyl)amino]-5,7-dinitro-2,1,3-benzoxadiazole; N'-(5,7-dinitro-2,1,3-benzoxadiazol-4-yl)-N,N-dimethyl-1,4-diaminobenzene; 3-[(5,7-dinitro-2,1,3-benzoxadiazol-4-yl)amino]phenol; 4-(N-methyl-N-phenylamino)-7-nitro-2,1,3-benzoxadiazole; 4-(N-ethyl-N-phenylamino)-7-nitro-2,1,3-benzoxadiazole and 4-[N-(2'-hydroxyethyl)-N-[4-di-(2'-hydroxyethyl)-2-nitrophenylamino]-7-nitro-2,1,3-benzoxadiazole.

5(amended). Cosmetic preparation according to claim 8, wherein said at least one derivative of general formula (I) is selected from the group consisting of 4-nitro-7-methoxy-2,1,3-benzoxadiazole; 4-nitro-7-ethoxy-2,1,3-benzoxadiazole; 4-nitro-7-phenoxy-2,1,3-benzoxadiazole; 7-nitro-4-(N-phenylamino)-2,1,3-benzoxadiazole; 4-[N-(4'-methylphenyl)aminol]-7-nitro-2,1,3-benzoxadiazole;

4-[N-(4'-methoxyphenyl)-amino]-7-nitro-2,1,3-benzoxadiazole; 4-[(7-nitro-2,1,3-benzoxadiazolo-4-yl)-amino]phenol; 3-[(7-nitro-2,1,3-benzoxadiazolo-4-yl)-amino]phenol; 2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]phenol; 4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-3-chloro-5-nitrophenol; N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-1,4-diaminobenzene; N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-2-(2'-hydroxyethyl)-1,4-diaminobenzene; N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-2-(1'-hydroxyethyl)-1,4-diaminobenzene; N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-2-(methoxymethyl)-1,4-diaminobenzene; N,N-dimethyl-N'-(7-nitro-2,1,3-benzoxadiazol-4-yl)-1,4-diamino-benzene; N,N-di-(2'-hydroxyethyl)-N'-(7-nitro-2,1,3-benzoxadiazol-4-yl)-2-nitro-1,4-diaminobenzene and 4-[N-(2'-hydroxyethyl)-N-[4-di-(2'-hydroxy-ethyl)-2-nitrophenylamino]-7-nitro-2,1,3-benzoxadiazole.

6(amended). Cosmetic preparation according to claim 8, and containing said at least one 4-nitro-2,1,3-benzoxadiazole derivative of general formula (I) in an amount from 0.01 to 10 wt. %.

9(amended). Cosmetic preparation according to claim 8, further comprising at least one direct dye compound selected from the group consisting of anionic dyes, cationic dyes, nitro dyes, azo dyes, anthraquinone dyes, triphenylmethane dyes and disperse dyes.

1.0(amended). Cosmetic preparation according to claim 8 or 9, in the form of a shade fixative or color fixative and further comprising at least one natural or synthetic polymer or at least one modified polymer of natural origin.

11(amended). Cosmetic preparation according to one of claims 8 to 10, further comprising an oxidation dye precursor.

12(amended). Cosmetic preparation according to one of claims 8 to 11, further comprising an oxidant mixed with said at least one 4-nitro-2,1,3-benzoxadiazole derivative.

13(amended). Cosmetic preparation according to one of claims 8 to 12, consisting of a hair colorant composition.

REMARKS

This is a simultaneous amendment of the English translation of U.S. National Stage application corresponding to International Patent Application PCT/EP 01/07497.

Claims 1 and 7 have been canceled and "use" claims 2 to 6, which are non-statutory in U.S. Practice, have been amended so that they now depend on cosmetic preparation claim 8 and are dependent preparation claims. Also dependent preparation claims 9 to 13 have been amended. Minor changes in